The investigational oral tyrosine kinase inhibitor (TKI) zongertinib showed promise in patients with previously treated HER2 ...

Announcing a new article publication for BIO Integration journal. Bladder cancer (BLCA) is one of the most common malignancies and the second most frequent urogenital tract tumor.

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

This study highlights the promising potential of LC–MS as a powerful tool for mAb quality control within the context of upstream processing.

The data, presented in a poster titled "AP402, a bispecific antibody targeting p95HER2 and CD137, shows potent antitumor activity," highlight the therapeutic potential of AP402 to address ...

Boehringer Ingelheim’s drug candidate for human epidermal growth factor receptor 2 (HER2)-mutated non-small cell lung cancer ...

Findings demonstrate ATYR2810's anti-tumor activity and increased survival in a model of glioblastoma multiforme (GBM), a primary form of brain cancer.

Phase 1b Beamion LUNG-1 trial data at AACR 2025 showed zongertinib yielded responses in pretreated HER2-mutant NSCLC, ...

INGELHEIM, Germany and RIDGEFIELD, Conn., April 28, 2025 /PRNewswire/ -- Boehringer Ingelheim reported new and updated data from the Beamion LUNG-1 trial evaluating zongertinib in previously treated ...

According to reports from industry insiders the Global AI in Diabetic Retinopathy market is projected to continue to grow at a substantial rate for years to come. According to Metastat, Global AI in ...

In a Phase I study presented at AACR's annual meeting, 71 percent of patients who hadn't received a prior anti-HER2 ADC responded to the drug.